Morris Robert E
Helen Keller Foundation for Research and Education, Birmingham, Alabama, USA.
Retina Specialists of Alabama, LLC, Birmingham, Alabama, USA.
Clin Ophthalmol. 2022 Jun 1;16:1653-1663. doi: 10.2147/OPTH.S361557. eCollection 2022.
Primary opacities that develop in the aging vitreous, commonly termed "floaters," were once considered merely a nuisance, not justifying any risk of surgical removal. However, vitreoretinal specialists are increasingly recognizing that extensive symptomatic vitreous opacities (SVO) that substantially interfere with activities that critically depend on vision (daily visual activities, DVA), constituting degenerative vitreous syndrome (DVS, see http://floaterstories.com), warrant removal albeit with minimal risk - but no description of how to reduce vitrectomy risks to least possible has been forthcoming. We here describe such a method.
The safest possible removal of extensive SVO as described herein was attained by an operation specifically designed for DVS treatment (vitreous opacity vitrectomy, VOV), rather than as only a means of achieving subsequent retinal surgery in the same procedure, as is usually the case. We retrospectively reviewed the outcomes of 100 consecutive VOV operations (in 81 patients, average age 66) performed with ultra-high speed, 27-gauge vitrectomy probes.
All eyes rapidly achieved continuously clear vision, and no eye developed a clinically significant complication during a year of follow-up. Three small, existent retinal breaks were discovered prior to peripheral vitrectomy and one apparently iatrogenic retinal tear was found at VOV completion, when each was treated. In the eyes that were not pseudophakic, postoperative nuclear sclerosis progression was successfully managed by subsequent cataract extraction.
The goals of VOV for DVS are to safely restore continuously clear vision by performing tractionless vitreous removal with respect to the retina and to reduce the lifetime risk of retinal detachment, both by such vitreous removal and by microscopic examination of the peripheral retina under anesthesia (MEPRUA), guiding appropriate prophylactic retinopexy. The otherwise healthy DVS eyes so treated warrant this specific form of vitrectomy, continually focused on achieving least possible risk, to maintain an acceptable risk/benefit ratio.
在老化玻璃体中出现的原发性混浊,通常称为“飞蚊症”,曾被认为只是一种麻烦,不值得承担手术切除的任何风险。然而,玻璃体视网膜专家越来越认识到,广泛的有症状玻璃体混浊(SVO)严重干扰严重依赖视力的活动(日常视觉活动,DVA),构成退行性玻璃体综合征(DVS,见http://floaterstories.com),尽管风险极小,但仍需切除——但尚未有关于如何将玻璃体切除术风险降至最低的描述。我们在此描述这样一种方法。
本文所述的广泛SVO的最安全切除是通过专门为DVS治疗设计的手术(玻璃体混浊玻璃体切除术,VOV)实现的,而不是像通常那样仅作为在同一手术中进行后续视网膜手术的一种手段。我们回顾性分析了100例连续的VOV手术(81例患者,平均年龄66岁)的结果,这些手术使用超高速27G玻璃体切除探头进行。
所有患眼均迅速获得持续清晰的视力,且在一年的随访期间没有患眼出现具有临床意义的并发症。在周边玻璃体切除术前发现3个小的现存视网膜裂孔,在VOV完成时发现1个明显的医源性视网膜裂孔,均进行了相应处理。在非人工晶状体眼,术后核硬化进展通过后续的白内障摘除成功控制。
DVS的VOV目标是通过对视网膜进行无牵引的玻璃体切除安全地恢复持续清晰的视力,并通过这种玻璃体切除以及在麻醉下对周边视网膜进行显微镜检查(MEPRUA)来降低视网膜脱离的终生风险,指导适当的预防性视网膜光凝。如此治疗的原本健康的DVS眼值得进行这种特定形式的玻璃体切除术,持续关注将风险降至最低,以维持可接受的风险/效益比。